GlassScriptPhysician profile
Melissa Rainwater
NPI 1073557005
$2,533.75
in general payments reported to CMS, 2019-2025
24 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $111 · 2021: $571 · 2022: $745 · 2023: $423 · 2024: $211 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $865.51 | 2019-2023 | |
| Astellas Pharma US INC | $274.65 | 2022-2024 | Veozah |
| Mayne Pharma Commercial LLC | $244.44 | 2022-2025 | |
| Organon LLC | $142.19 | 2022-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $122.13 | 2019-2024 | |
| Pfizer INC. | $116.44 | 2021-2025 | |
| Exeltis, USA INC. | $114.52 | 2021-2023 | Slynd |
| Meditrina | $74.80 | 2022-2024 | |
| Axonics, INC. | $70.10 | 2022-2023 | Axonics, Bulkamid |
| Therapeuticsmd, INC. | $69.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $61.12 | 2019-2021 | |
| Millicent US INC | $49.04 | 2025 | Intrarosa, Femlyv |
| Avion Pharmaceuticals | $47.02 | 2022 | |
| Biogen, INC. | $44.54 | 2025 | Zurzuvae |
| Innovation Technologies INC | $33.09 | 2023 | Irrisept |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.05 | 2022-2024 | Thinprep 2000 Processor, Aptima |
| Novo Nordisk INC | $29.85 | 2023 | |
| Boston Scientific Corporation | $28.52 | 2025 | Bulkamid |
| Evofem Biosciences, INC. | $27.74 | 2022 | |
| Amag Pharmaceuticals, INC. | $27.21 | 2019 | |
| Myovant Sciences INC. | $17.40 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.62 | 2023 | Exparel |
| Roche Diagnostics Corporation | $15.13 | 2019 | |
| Covidien LP | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Rainwater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.